Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2026)
Amylyx Pharmaceuticals (AMLX) posted quarterly Current Assets of $285.0 million for Q1 2026, up 31.87% year-over-year from $216.1 million in Q1 2025, and down 11.94% quarter-over-quarter from $323.7 million in Q4 2025.
Amylyx Pharmaceuticals (AMLX) Current Assets (2021 - 2026) Analysis & Trends
Amylyx Pharmaceuticals' Current Assets history runs 6 years deep, the most recent figure standing at $285.0 million for Q1 2026.
- In Q1 2026, Current Assets rose 31.87% year-over-year to $285.0 million; the TTM figure through Mar 2026 stood at $285.0 million (up 31.87% YoY), while the FY2025 annual figure was $323.7 million, up 70.86% from the prior year.
- Current Assets for Q1 2026 stood at $285.0 million, down from $323.7 million in the prior quarter.
- The five-year high for Current Assets was $464.7 million in Q4 2023, with the low at $172.2 million in Q3 2022.
- The 5-year median for Current Assets is $323.7 million (2025), against an average of $311.1 million.
- The sharpest annual moves came in 2022 and 2024: Current Assets soared 264.11% in 2022, then sank 59.23% in 2024.
- Amylyx Pharmaceuticals' Current Assets stood at $382.1 million in 2022, then climbed by 21.6% to $464.7 million in 2023, then tumbled by 59.23% to $189.4 million in 2024, then jumped by 70.86% to $323.7 million in 2025, then decreased by 11.94% to $285.0 million in 2026.
- Business Quant data shows AMLX's Current Assets at $285.0 million in Q1 2026, $323.7 million in Q4 2025, and $353.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.71 Bn | 42.75 Bn | - | 5.76 Bn |
| 2 | Teva Pharmaceutical Industries | 43.11 Bn | 39.45 Bn | 2.15 Bn | 13.76 Bn |
| 3 | Zoetis | 31.62 Bn | 29.94 Bn | 1.05 Bn | 6.36 Bn |
| 4 | Takeda Pharmaceutical | 28.72 Bn | 22.92 Bn | 5.10 Bn | 19.76 Bn |
| 5 | United Therapeutics | 22.33 Bn | 19.67 Bn | 683.80 Mn | 3.48 Bn |
| 6 | Viatris | 18.83 Bn | 17.95 Bn | 1.46 Bn | 10.06 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 1.64 Bn |
| 8 | Elanco Animal Health | 12.10 Bn | 11.57 Bn | 798.00 Mn | 3.80 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 3.22 Bn |
| 10 | Amylyx Pharmaceuticals | 4.28 Bn | 4.28 Bn | - | 256.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 256.34 Mn |
| Mar 31, 2026 | 285.02 Mn |
| Dec 31, 2025 | 323.67 Mn |
| Sep 30, 2025 | 353.38 Mn |
| Jun 30, 2025 | 186.89 Mn |
| Mar 31, 2025 | 216.14 Mn |
| Dec 31, 2024 | 189.43 Mn |
| Sep 30, 2024 | 245.26 Mn |
| Jun 30, 2024 | 326.72 Mn |
| Mar 31, 2024 | 410.53 Mn |
| Dec 31, 2023 | 464.67 Mn |
| Sep 30, 2023 | 434.11 Mn |
| Jun 30, 2023 | 427.39 Mn |
| Mar 31, 2023 | 389.05 Mn |
| Dec 31, 2022 | 382.13 Mn |
| Sep 30, 2022 | 172.20 Mn |
| Jun 30, 2022 | 216.14 Mn |
| Mar 31, 2022 | 265.49 Mn |
| Dec 31, 2021 | 104.95 Mn |